Published in Cancer Weekly, February 10th, 2009
The establishment of a US-based R&D and commercial operation represents attainment of one of the Helsinn Group's corporate strategic goals. "We are thrilled at this very important opportunity to increase Helsinn's value with a direct presence in the major pharmaceutical market of the world," said Riccardo Braglia, CEO of the Helsinn Group. "The acquisition of Sapphire Therapeutics will also allow us to expand our current pipeline of products in existing, focused...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2009-02-10)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.